Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Recovery Delivered vs ShedRx

Two GLP-1 desks, one scoreboard. We put Recovery Delivered and ShedRx head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 134 · Grade C

Recovery Delivered

Visit Recovery Delivered Full brief →
vs
Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 71 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Recovery Delivered a bad call — it's best for readers who want cheap compounded glp-1 with an included provider video visit and fast home delivery. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
48
86
Supply Reliability
71
86
Transparency
88
84
Access Breadth
80
85
Clinical Oversight
76
85
Track Record
69
86
Recovery DeliveredBrief Score 71 · 87ShedRx

Price, coverage & the tracker

Recovery DeliveredShedRx
Brief Score71/100 (C)87/100 (B+)
SemaglutideFrom $199/mo (starting dose, compounded)$199/mo
TirzepatideFrom $219/mo (2.5 mg dose, compounded)$299/mo
Coverage32 statesNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerNewnew to the tracker, no prior readingFallingprice falling

Recovery Delivered: New to the tracker on 1 August 2026. The published line reads From $199/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.